Skip to main content
Premium Trial:

Request an Annual Quote

The Thin Shield of R&D

Bristol-Myers Squibb announced plans to lay off 4,300 employees and close more than half of its manufacturing plants in a cost-saving, "right-sizing" move. Followed by Pfizer and Merck, it's the third big pharma company to take action against the looming generics competition. In the Pipeline's Derek Lowe thinks it's not a bad thing, as long as R&D is left alone to do what they do best -- discover new drug compounds.


The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.